January 27, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG Oncology would like to thank our attendees for joining us in Phoenix for an eventful and engaging NRG Meeting! We would also like to thank those who joined us virtually for our online sessions. Please check the NRG Oncology Meeting Webpages in the coming days for session presentation slide postings as they become available.

We hope that you join us for our Summer Meeting, NRG2025 in Washington DC - July 24-26, 2025.

AMENDMENTS

GYNECOLOGIC

The following protocol amendment is in response to an NCI action letter for CTEP-supported studies that involve ipatasertib:

NRG-GY028: Amendment 5; version date: January 3, 2025 (posted on CTSU)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BREAST

NRG-BR009/OFSET: November 2024 Webinar slides (posted on CTSU) 

4. CANCER PREVENTION & CONTROL

NRG-CC008: As a reminder to sites, translations of the patient tools are available on the CTSU website. See memo for details (posted on CTSU).

NRG-CC010: The study is open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

5. GYNECOLOGIC

NRG-GY026: Please note, the post-chemo cfDNA Whole Blood (WB03) should only be collected if the Pre-Treatment cfDNA Whole Blood (WB01) was collected.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY036: This study is open to NRG sites in Japan and South Korea. 

6. HEAD & NECK

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

7. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, NRG-BR009, NRG-BN014, NRG-CC011, NRG-CC013, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for February 12, 2025.

Drug Safety and Investigator’s Brochure (IB*) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. Winter Meeting Slides

Check the NRG Oncology Meeting Webpages in the coming days for session presentation slide postings as they become available.

2. PRESS RELEASE: Radiotherapy with Cetuximab may be superior to radiotherapy alone for selected patients who underwent surgery for head and neck cancer

Recent results from the phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) showed that radiotherapy with cetuximab demonstrated superiority as measured by improved disease-free survival, a secondary endpoint. The study also showed no increase in long-term toxicity. The trial results, however, did not show a statistically significant improvement in overall survival, the primary endpoint. These results were recently published in the Journal of Clinical Oncology, one of the highest impact cancer journals in the world. Read the press release

3. NEW Training Available on CTSU/CLASS - Patient Reported Outcomes, Introduction to Study Design and Speciliazed Study Designs

NRG Oncology recently launched three new education modules on the CTSU/CLASS platform. You can find these modules by logging into CTSU and clicking the CLASS tab. For more detailed instructions, click here. 

4. REGISTER TODAY: Distinguishing Immune-Related vs. Radiation Pneumonitis Following Thoracic Radiotherapy Webinar

Join the ACR® for an informative webinar on February 19^th from 5:00-6:00pm ET covering how to distinguish immune-related vs. radiation pneumonitis following thoracic radiotherapy (RT).

National experts in radiology will discuss interpreting findings seen on post-treatment CT and PET imaging after RT for thoracic malignancies; understanding the pathophysiology, clinical features, and diagnostic strategies to differentiate between radiation-related and immune-related pneumonitis; and understanding the management of radiation and immune-related pneumonitis. This webinar is relevant to all radiation and medical oncologists.  

Hosts: Rituraj Upadhyay, MD, Emile Gogineni, DO, and Arya Amini, MD

Speakers: Drew Moghanaki, MD and Sharyn Katz, MD

Register here today

5. Translational Science Committee Soliciting Pilot Projects for Inclusion in the NRG UG1 Translational Science Center Application

The NRG Oncology Translational Science Committee is soliciting one-page proposals (with Specific Aims) for pilot projects to incorporate into their “Network Group Integrated Translational Science Center” application due in February 2025. More information available here.

6. NRG Oncology Seeking Candidate for Deputy NCORP PI Role

We are seeking nominations for the position of Deputy NCORP PI. The NCI Community Oncology Research Program (NCORP) brings cancer research studies and results to patients in a variety of community settings across the United States. NRG is one of seven NCORP research bases and one of only four focused on adults with cancer. The focus of the NRG NCORP is on cancer control, cancer prevention and cancer care delivery. Patient reported outcomes and health disparities are cross-cutting themes incorporated into most NCORP protocols as well as NRG treatment trials. The deadline for the application submission is February 14, 2025. Read more

7. NRG Oncology Seeking Candidate for Cancer Control Committee Chair Role

We are seeking nominations for the position of Chair of the NRG NCORP Cancer Control Committee. Candidates for this position should have an active program of funded research and publications focused on the NRG cancer control priorities of improvement or delay in decline of neurocognitive function, reducing gender specific symptoms such as lymphedema and sexual function, and testing therapeutic delivery modifications to improve QoL and cost-effectiveness in localized cancers while maintaining efficacy. Candidates should have a track record of mentorship and a willingness to provide timely consultation to members and liaisons of NRG committees as concepts and protocols are being developed. In addition to leading the NRG Cancer Control Committee, this candidate will also serve as a co-chair of the Cancer Prevention and Control (CPC) Committee. This individual will work closely with the CPC on the priorities of the overall committee. The deadline for the application submission is February 14, 2025. Read more

8. NRG Oncology Seeking Sarcoma Working Group Chair & Vice Chair

NRG Oncology seeks two dynamic individuals who will bring outstanding leadership skills, a collaborative team science spirit, and sarcoma expertise to a vibrant and highly motivated national Cooperative Group network by joining us as Sarcoma Subcommittee Chair and Vice Chair. 

We are looking for candidates with nationally recognized expertise in sarcoma. Candidates must be at an NRG Oncology Member Institution and eligible to receive federal funding. Nominal funds from federal grants to offset related effort and travel to NRG Oncology meetings is provided. Additionally, candidates are required to have either completed the demographic information or have formally elected to opt-out as per the NRG Oncology Demographic Data Initiative. The deadline for the application submission is February 14, 2025. Read more

9. NRG Member Demographics Data Collection Initiative

We are excited to introduce the NRG Member Demographics Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

REMINDER: Any manuscript or abstract resulting from research conducted under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association.

Please reach out to NRG-Publications@NRGOncology.org as a first step to ensure all requirements are met.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

PUBLISHED ARTICLES

Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen SL, Gwede CK, Dicker AP, Yao M, Jordan RC, Dorth J, Lee N, Chan JW, Dunlap N, Bar-Ad V, Stokes WA, Chakravarti A, Sher D, Rao S, Harris J, Yom SS, Le QT; NRG Oncology RTOG 0920 Collaborating Team; TransSCOT Consortium. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. J Clin Oncol. 2025 Jan 22:JCO2401829. doi: 10.1200/JCO-24-01829. Epub ahead of print. PMID: 39841939. Read more

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 25-30, 2025; Chicago, IL

American Association for Thoracic Surgery (AATS); May 2-5, 2025; Seattle, WA

American Head & Neck Society (AHNS); May 14-15, 2025; New Orleans, LA

American Radium Society (ARS) Annual Meeting; Apr 3-6, 2025; Seattle, WA

American Society of Clinical Oncology (ASCO) GU; Feb 13-15, 2025; San Francisco, CA

American Surgical Association (ASA); Apr 24-26, 2025; San Diego, CA

European Society of Gynaecological Oncology (ESGO); Feb 20-23, 2025; Rome, Italy

Miami Breast Cancer Conference; Mar 6-9, 2025; Miami, FL

Society for Clinical Trials (SCT); May 18-21, 2025; Vancouver, BC

Society for Gynecologic Oncology (SGO); Mar 14-17, 2025; Seattle, WA

Society of Surgical Oncology (SSO) Annual Meeting; Mar 27-29, 2025; Tampa, FL

SSO – Advanced Cancer Therapies; Feb 14-17, 2025; Scottsdale, AZ

St. Gallen Breast Cancer Conference; Mar 12-15, 2025; Vienna Austria

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Brachytherapy Society (ABS); Jun 18-21, 2025; Nashville, TN; Submission deadline Feb 4, 2025, 6:00 pm PT

American College of Radiology (ACR); May 3-7, 2025; Washington, DC; Submission deadline Jan 27, 2025, 11:59 pm ET

American Society of Breast Surgeons (ASBrS); Apr 30-May 4, 2025; Las Vegas, NV; LBA Feb 5, 2025 (placeholder required)

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL; Submission deadline Jan 28, 2025; LBA Mar 5, 2025 (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); May 11-14, 2025; San Diego, CA; LBA and Clinical Trials Jan 29, 2025, 11:59 pm ET

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA; Due to publications committee Feb 11, 2025; Submission deadline Feb 25, 2025, 11:59 pm PT; LBA Jul 10, 2025, 11:59 pm PT

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB; Due to publications committee Feb 6, 2025; Submission deadline Feb 20, 2025

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; Due to publications committee Apr 25, 2025; Submission deadline May 13, 2025, 21:00 CET; LBA Sep 9, 2025, 21:00 CET (placeholder required)

ESMO Breast Cancer; May 14-16, 2025; Munich, Germany; Due to publications committee Jan 28, 2025; Submission deadline Feb 11, 2025, 21:00 CET; LBA Apr 15, 2025, 21:00 CET (placeholder required)

ESMO Gynaecological Cancers; Jun 19-21, 2025; Vienna, Austria; Due to publications committee Mar 18, 2025; Submission deadline Apr 1, 2025, 21:00 CET

European Society for Radiotherapy and Oncology (ESTRO); May 2-6, 2025; Vienna, Austria; LBA Mar 19, 2025

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI; Due to publications committee Mar 25, 2025; Submission deadline Apr 7, 2025

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL; Due to publications committee Apr 23, 2025; Submission deadline May 7, 2025, Noon CT